Citadel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,000
| Closed | -$69.2K | – | 13855 |
|
|
2025
Q1 | $69.2K | Sell |
6,000
-30,600
| -84% | -$312K | ﹤0.01% | 11931 |
|
|
2024
Q4 | $310K | Sell |
36,600
-61,400
| -63% | -$636K | ﹤0.01% | 9587 |
|
|
2024
Q3 | $1.13M | Buy |
98,000
+88,300
| +910% | +$1.11M | ﹤0.01% | 6627 |
|
|
2024
Q2 | $114K | Sell |
9,700
-20,400
| -68% | -$238K | ﹤0.01% | 10723 |
|
|
2024
Q1 | $357K | Sell |
30,100
-1,100
| -4% | -$14.7K | ﹤0.01% | 9100 |
|
|
2023
Q4 | $382K | Buy |
31,200
+29,700
| +1,980% | +$270K | ﹤0.01% | 8662 |
|
|
2023
Q3 | $14.4K | Buy |
+1,500
| New | +$15.3K | ﹤0.01% | 12869 |
|
|
2023
Q1 | – | Sell |
-13,300
| Closed | -$89.9K | – | 15118 |
|
|
2022
Q4 | $89.9K | Buy |
+13,300
| New | +$71.2K | ﹤0.01% | 11363 |
|
|
2021
Q4 | – | Sell |
-27,900
| Closed | -$487K | – | 14313 |
|
|
2021
Q3 | $487K | Sell |
27,900
-16,900
| -38% | -$343K | ﹤0.01% | 9936 |
|
|
2021
Q2 | $1.07M | Sell |
44,800
-100,800
| -69% | -$2.64M | ﹤0.01% | 8193 |
|
|
2021
Q1 | $3.74M | Sell |
145,600
-35,800
| -20% | -$941K | ﹤0.01% | 4925 |
|
|
2020
Q4 | $3.44M | Buy |
+181,400
| New | +$3.11M | ﹤0.01% | 4348 |
|
Other funds holding KALV
Citadel Advisors's KALV Position: Q2 2026 in Review
Citadel Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 97,726 shares — an estimated $1.97M sold.
Citadel Advisors first reported a position in KALV in Q2 2015 and held it in 24 quarters. The position peaked at $9.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Citadel Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 97,726 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.97M.
- Citadel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's KalVista Pharmaceuticals position peaked at $9.6M in Q4 2023.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.